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Background: Recently, lymph node metastasis (LNM) has been regarded as an important factor influencing
loco-regional recurrence and survival rate in papillary thyroid cancer (PTC) patients. The aims of this study were to
investigate the detection rate and metastasis rate of the Delphian lymph node (DLN) and clinical patterns related to
regional LNM, and to examine how DLN metastasis affects PTC treatment.
Methods: We reviewed the medical records of 413 patients with pathologically confirmed PTC from among 452
patients who underwent thyroid surgery between January 2010 and October 2010 in the Department of Endocrine
Surgery at Kosin University Gospel Hospital in Busan, South Korea.
Results: Multivariate analyses revealed a significantly higher proportion of cases with lymphovascular invasion
(56.6% vs. 12.5%, P <0.001), central neck node metastasis (88.6% vs. 34.5%, P <0.001) and lateral neck node
metastasis (47.2% vs. 10.2%, P <0.005) among cases with DLN metastasis compared to those without. The negative
predictive value (NPV) of DLN metastasis with regard to the presence of contralateral central LNM for cases with a
tumor size 1 cm or smaller than 1 cm was found to be 93.3% (127/136).
Conclusion: When DLN metastasis is not detected in papillary thyroid microcarcinomas (PTMC), thyroid lobectomy
on the affected side and ipsilateral central neck lymph node dissection should be sufficient. In addition, even in
cases where lateral neck LNM is not detected on preoperative examination, if DLN metastasis is detected
postoperatively, more careful attention should be paid to the lateral neck nodes during follow-up.
Keywords: Delphian lymph node, Papillary thyroid cancer, Central neck lymph nodeBackground
Now the most commonly observed endocrine organ
cancer is thyroid cancer [1,2]. Therefore, many studies
have been performed on the surgical scope of thyroid
cancer and on the treatment prognosis [1-4].
With papillary thyroid cancer (PTC), the effect of cer-
vical lymph node metastasis (LNM) has been a less signifi-
cant factor influencing the survival rate [5], but several
recent studies reported that LNM has an effect on loco-
regional recurrence and survival rate [1,3,6-11]. The devel-
opment of ultrasonography that could be used before
surgery made the evaluation of disease progression less* Correspondence: gskjh@hanafos.com
1Department of Surgery, Kosin University College of Medicine, 34
Amnam-dong, Seo-gu, Busan, Korea
Full list of author information is available at the end of the article
© 2012 Kim et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcomplicated, and the use of frozen section biopsy in de-
termining the scope of surgery intraoperatively, along
with careful lymph node dissection, may lower the lymph
node recurrence rate to improve the disease-free survival
[12-14].
Level VI nodes are the most common nodal regions
found to harbor metastasis and are made up of the
Delphian (prelaryngeal), paratracheal and pretracheal
nodes. Among Level VI nodes, the Delphian lymph node
(DLN) sits directly anterior to the cricothyroid mem-
brane between the cricothyroid muscles and is perhaps
the most important of the level VI nodes surgically
because it is the first lymph node encountered during
total thyroidectomy [15,16]. Although debate remains
on how lymph node metastasis progresses, it is common
knowledge that the pretracheal lymph nodes are located. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The rate of detection and metastasis of Delphian
lymph nodes (n = 413)
Lymph node metastasis 187 (187/413, 45.3%)
Delphian lymph node detection 308 (308/413, 74.6%)
Delphian lymph node metastasis 53 (53/308, 17.2%)
Mean no. of Delphian lymph nodes 2.23
Mean no. of Delphian lymph node metastases 1.4
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mediastinum, and the DLNs are drained out toward the
lateral neck following the superior thyroid artery [15-17].
Especially in laryngeal cancer, DLN metastasis is known
as a predictor of extensive LNM, high recurrence rate
and increased mortality rate. Therefore, it could serve
as a useful parameter for determining the appropriate
surgical treatment method, the need for additional treat-
ment and prognosis. In thyroid cancer, however, due to
the limited data on DLN metastasis, its clinical signifi-
cance is still debated [15,16,18-21].
The aim of the present study was to determine whether
the presence of DLN metastasis could be utilized in plan-
ning the surgical scope for thyroid cancer and selecting
treatment options. We investigated the detection and
metastasis rates and the associated clinical patterns of
the Delphian lymph node in thyroid cancer, including
the relationship with further metastasis in the central
compartment.
Patients and methods
We reviewed the medical records of 413 patients with
pathologically confirmed PTC from among a total of
452 patients who underwent thyroid surgery between
January and October 2010 at the Department of Endo-
crine Surgery of Kosin University Gospel Hospital in
Busan, South Korea. We also gathered data on cervical
LNM by the presence of DLN metastases.
After removing all tissues superior to thyroid isthmus
and anterior to the cricothyroid membrane where the
DLN are located, the presence of DLN and the occur-
rence of metastasis were microscopically diagnosed. The
pretracheal lymph nodes that are detected in front of
the central neck are referred to as sub-DLN, and DLN
dissections that were performed at our hospital also
included dissections of lymph nodes that were located in
front of the thyroid cartilage and cricoid cartilage. Sur-
geries were performed following a typical thyroid dis-
section method and level VI dissection was performed in
all patients, including dissections of pretracheal lymph
nodes, paratracheal lymph nodes, and DLN. Based on
pathological results, we investigated the relationship be-
tween the presence of DLN metastasis and age, tumor
size, invasion of the surrounding tissues of the thyroid,
lymphovascular invasion, number of central LNMs and
the number of lateral neck LNMs. To further evaluate
the relationship between DLN metastasis and lateral
neck LNM, we also included cases in whom lateral neck
lymph node dissection was performed. The central neck
lymph node classification was assigned, excluding DLN,
to investigate the relationship with further metastasis in
the central compartment. The Chi-square test and
Fisher’s exact test were used for statistical analysis using
SPSS 17.0(SPSS Inc., Chicago, IL, USA) and test resultswere considered statistically significant when the prob-
ability was less than 0.05. The extent of correlation be-
tween variables was confirmed using a partial correlation
analysis.
Results
Among 413 patients who underwent thyroid dissection
and cervical lymph node dissection due to the presence
of PTC, 187 patients (45.3%) were found to have cervical
LNM. The DLN was observed in 308 patients (74.6%)
and the mean number of DLNs was 2.2. DLN metastasis
was observed in 53 patients (17.2%), corresponding to
12.8% of DLN metastases in a total of 413 patients. The
mean number of metastasized DLNs was 1.4, as shown
in Table 1.
There was no statistically significant difference
observed between groups where DLN went detected/
undetected in the following categories: age at surgery,
sex distribution, multifocality, tumor size, thyroiditis,
lymphovascular invasion, capsule invasion, central neck
LNM, mean number of central lymph nodes removed,
lateral neck LNM, mean number of lateral lymph nodes
removed and metastasis. A statistically significant differ-
ence was observed (2.02 vs. 1.25, P <0.001) only when
the mean number of central neck lymph nodes in the
two groups was compared, as shown in Table 2.
Type of surgery in patients with Delphian lymph
nodes were Total thyroidectomy with CCND (213/308,
69.1%), Lobectomy with isthmectomy with CCND
(44/308, 14.3%), Total thyroidectomy with CCND with
MRND (51/308, 16.6%), as shown in Table 3.
When cases with DLN metastasis were compared to
cases without, univariate analyses showed a statistically
significant difference in the following variables: multi-
focality (1.8 vs. 1.0, P <0.001), tumor size larger than
1 cm (66.0% vs. 44.0%, P <0.003), lymphovascular
invasion (56.6% vs. 12.5%, P <0.001), capsule invasion
(79.2% vs. 51.3%, P <0.001), central neck LNM (88.6% vs.
34.5%, P <0.001) and lateral neck LNM (45.3% vs. 10.2%,
P <0.001), as shown in Table 4.
When multivariate analyses were performed, statis-
tical significant differences were found in lymphovas-
cular invasion (56.6% vs. 12.5%, P <0.005), central
neck LNM (88.6% vs. 34.5%, P <0.001) and lateral
neck LNM (47.2% vs. 10.2%, P <0.016). However, no
Table 2 Demographics of patients with papillary thyroid cancer with and without Delphian lymph nodes
Delphian lymph node existence P-value
Present (n =308) Absent (n =105)
Age 46.6 ± 10.9 (18 to 75) 50.0 ± 11.8 (26 to 74) 0.346
<45 133 (43.2%) 35 (33.3%)
≥45 175 (56.8%) 70 (66.7%)
Sex (F/M) 263/45 90/15 0.926
Multifocality 1.15 (1 to 11) 1.03 (1 to 7) 0.534
Tumor size (mm) 11.37 ± 7.39 (0.5 to 58) 11.43 ± 9.44 (1.5 to 80) 0.864
≤1 161 (52.3%) 60 (58.3%)
>1 147 (47.7%) 45 (42.9%)
Thyroditis 0.052
Present 106 (34.4%) 25 (23.8%)
Absent 202 (65.6%) 80 (76.2%)
Lymphovascular invasion 0.776
Present 62 (20.1%) 19 (18.1%)
Absent 246 (79.9%) 86 (81.9%)
Capsule invasion 0.479
Present 184 (59.7%) 57 (54.3%)
Absent 124 (40.3%) 48 (45.7%)
Central metastasis 0.305
Present 140 (45.5%) 42 (40.0%)
Absent 168 (54.5%) 63 (60.0%)
Mean no. of central nodes removed 12.08 (0-35) 8.83 (1-51) 0.097
Mean no. of central node metastases 2.02 (0-25) 1.25 (0-8) 0.001
Lateral metastasis 0.098
Present 51 (16.2%) 10 (9.5%)
Absent 257 (83.8%) 95 (90.5%)
Mean no. of lateral nodes removed 19.16 (1 to 59) 23.85 (3 to 71) 0.812
Mean no. of lateral node metastases 5.0 (0 to 36) 3.54 (0 to 9) 0.232
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capsule invasion (79.2% vs. 51.3%, P = 0.849), tumor
size larger than 1 cm (66.0% vs. 44.0%, P = 0.135),
multifocality(1.8 vs. 1.0, P = 0.268), age (44.7 vs. 46.9,
P = 0.175) and thyroiditis (26.4% vs. 35.7%, P = 0.169), as
shown in Table 4.
Central neck LNM was detected in 47 among 53 cases
of DLN metastasis (88.6%), while central LNM was
observed in 88 of 255 (34.5%) patients without DLNTable 3 Type of surgery in patients with Delphian lymph
nodes who underwent surgery for papillary thyroid
cancer
Type of surgery No. of patients (n = 308)
Total thyroidectomy c CCND 213 (213/308, 69.1%)
Lobectomy c isthmectomy c CCND 44 (44/308, 14.3%)
Total thyroidectomy c CCND c MRND 51 (51/308, 16.6%)metastasis; a significant difference (P <0.001). In other
words, the presence of DLN metastasis was associated
with an 11.7-fold higher frequency of central neck LNM
compared to cases without DLN metastasis. In addition,
the number of DLN metastases was correlated with
central neck LNM metastasis (correlation coefficient =
0.656, P <0.01). Lateral neck LNM was detected in 25
of 53 DLN metastasis cases (47.2%), a proportion that
was significantly different compared to cases of lateral
neck LNM in which DLN metastasis was not detected
(26 of 255 cases, 10.2%; P <0.001). This indicates that
the presence of DLN metastasis is associated with a
4.4-fold higher frequency of lateral neck LNM com-
pared to when DLN metastasis was absent (Table 5).
When patients who underwent lateral neck lymph
node dissection were excluded, contralateral central
neck LNM was detected in 13 of 31 (41.9%) patients
with DLN metastasis and in 22 of 226 (9.7%) patients
Table 4 Univariate and multivariate analysis of Delphian lymph node metastasis in patients with papillary thyroid
cancer
Delphian lymph node metastasis Univariate analysis Multivariate analysis
Present (n = 53) Absent (n = 255) P-value P-value CI
Age 44.7 ± 12.1 (19 to 73) 46.9 ± 10.6 (18 to 75) 0.175
<45 29 (54.7%) 104 (40.8%)
≥45 24 (45.3%) 151 (59.2%)
Multifocality 1.8 (1 to 11] 1.0 (1 to 10] 0.001 0.268 −0.034 to approximately 0.009
Tumor size(mm) 15.7 ± 10.4 (2 to 58) 10.5 ± 6.3 (0.5 to 38) 0.003 0.135 −0.010 to approximately 0.009
≤1 18 (34.0%) 143 (56.0%)
>1 35 (66.0%) 112 (44.0%)
Thyroditis 0.169
Present 14 (26.4%) 91 (35.7%)
Absent 39 (73.6%) 164 (64.3%)
Lymphvascular Invasion 0.001 0.005 0.047 to approximately 0.262
Present 30 (56.6%) 32 (12.5%)
Absent 23 (43.4%) 223 (87.5%)
Capsule Invasion 0.001 0.849 −0.066 to approximately ~0.080
Present 42 (79.2%) 131 (51.4%)
Absent 11 (20.8%) 124 (48.6%)
Central metastasis 53 88 0.001 0.001 0.157 to approximately 0.339
Contralateral central metastasis 28 (52.8%) 36 (14.1%)
Ipsilateral central metastasis 19 (35.8%) 52 (20.4%)
Non-metastasis 6 (11.3%)* 167 (65.6%)
Lateral metastasis 0.005 0.016 0.026 to approximately 0.250
Present 25 (47.2%) 26 (10.2%)
Absent 28 (52.8%) 229 (89.8%)
*six patients only Delphian lymph node metastasis.
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LNM depending upon the presence of DLN metastasis,
analysis revealed that the probability of not having
contralateral central neck LNM in the absence of DLN
metastasis absent (negative predictive value (NPV)) was
found to be 90.3% (204/226). In particular, when only
tumors diameter 1 cm or smaller than 1 cm in size were
analyzed, the NPV reached 93.3% (127/136), as shown in
Table 7.
Discussion
PTC is most frequently observed among thyroid cancers.
It generally grows slowly, but requires careful surgery
and follow-up observation after the surgery, since many
cases show aggressive LNM. Since LNM is frequentlyTable 5 Ability of Delphian lymph node metastasis to predict
Sensitivity Specificity PPV
Central node metastasis 35 97 89
Lateral node metastasis 48 89 45observed in PTC, many surgeons perform central neck
lymph node dissection on the affected side as a prevent-
ive measure [22-24]. In addition, since LNMs were
observed in papillary thyroid microcarcinoma (PTMC)
1 cm or smaller than 1 cm in size, many studies have
stressed the importance of monitoring for lymph node
recurrence [7,13,22,25-27]. Previously, the effect of cer-
vical LNM on survival rate for PTC was reported to
be low [5], but recent studies have reported significant
associations between LNM and loco-regional recur-
rence and survival rate [1,3,6-11].
Under such circumstances, attention has been directed
toward the clinical role of DLN in thyroid cancers, and
Isaacs et al. reported the probabilities of central neck
LNM and lateral neck LNM in the presence of DLNfurther central, lateral nodal metastasis
NPV Positive likelihood ratio Negative likelihood ratio
67 11.7 0.69
90 4.4 0.59
Table 6 Ipsilateral or contralateral central lymph node metastasis in patients with Delphian lymph node metastasis
(excluding those that underwent lateral neck node dissection)
Regardless of tumor size
Delphian lymph node metastasis
P-value Tumor size ≤1 cm










Contralateral central LNM 13 (41.9%) 22 (9.7%) 0.001 5 (41.7%) 9 (6.6%) 0.001
Ipsilateral central LNM 12 (38.7%) 40 (17.7%) 2 (16.7%) 20 (14.7%)
Non-central LNM 6 (19.4%)* 164 (72.6%) 5 (41.7%)* 107 (78.7%)
*Only Delphian lymph node metastasis.
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83%, respectively. The authors of that study also pro-
posed that the presence of central neck LNM is pre-
dictive of thyroid cancer progression, and claimed that
the presence of DLN metastasis is the most useful pre-
dictive factor [16]. In another study, Isaacs et al. also
reported the detection rate of DLN in PTC patients to
be 48.3% (87/180), lower than the 74.5% (308/413) dis-
covered in the present study, but they reported a DLN
metastasis rate of 20.7% (18/87), closer to the 17.4%
reported here [15].
Iyer et al. reported that DLN metastasis in thyroid
cancers is associated with extrathyroidal extension (ETE)
and the necessity of careful lymph node dissection and
frozen section biopsy during surgery because its pres-
ence is correlated with central neck LNM and lateral
neck LNM [20]. In the present study, the DLN me-
tastasis group had a significantly higher proportion of
patients with lymphovascular invasion (56.6% vs.
12.5%, P <0.005), further central neck LNM (88.6% vs.
34.5%, P <0.001), and lateral neck LNM (47.2% vs. 10.2%,
P <0.016) than the group in which DLN metastasis
was absent. The frequency of central neck LNM was
88.6% (47/53) in the group with DLN metastasis, and
DLN metastasis was also significantly correlated with
central neck LNM (correlation coefficient = 0.656,
P <0.01). These findings indicate that total thyroidectomy
and central neck lymph node dissection is the most
appropriate treatment choice in patients with DLN
metastasis.
Ito et al. reported that central neck LNM is not asso-
ciated with disease-free survival, and PTMC limited to
one side of the lobe may not perform central neck
lymph node dissection in the contralateral lobe in select
cases [5,8,13,24,27]. Roh et al. (2008) investigated the
metastasis pattern of central neck lymph nodes inTable 7 Ability of the Delphian lymph node metastasis to pre
Sensitivity Specificity
Contralateral central LNM 37 92
Contralateral central LNM (tumor size ≤1 cm) 35 95PTMC and reported that ipsilateral paratracheal LNM
was observed in 27 of 72 cases (37.5%) and contralateral
paratracheal LNM was observed in 1 of 57 cases (1.7%)
[27]. In the present study, if DLN metastasis was absent,
the NPV for contralateral central neck LNM was found
to be 90.3% (204/226). The NPV for LNMs tumor sized
1 cm or smaller than 1 cm was 93.3% (127/136), as
shown in Table 7. These results suggest that performing
thyroid lobectomy and ipsilateral central neck lymph
node dissection as a consequence of frozen section
biopsy results during surgery, in addition to limiting
contralateral central neck lymph node dissection to
select cases, could be sufficient for treating PTC patients.
Wada et al. (2003) reported a high recurrence rate of
lateral neck lymph node metastasis if lymph nodes were
visible with the naked eye during surgery (16.7% vs.
0.43%)1. In laryngeal cancer, the presence of DLN metas-
tasis increased lateral neck LNM, resulting in a high re-
currence rate and low survival rate. The presence of
DLN metastasis in laryngeal cancer is known to be a sig-
nificant prognostic factor [18,19,21]. Delbridge et al.
reported that the probability of having lateral neck LNM
when DLN metastasis was present in thyroid cancer
patients reached 74%, and proposed that DLN metastasis
should be used as a predictor of N1b stage [15,16]. In
the present study, the proportion of patients who experi-
enced lateral neck lymph node metastasis was signifi-
cantly higher in the DLN metastasis group (25 of
53 cases (47.2%)) than in the group in which DLN
metastasis was not detected (26 of 255 (10.2%);
P <0.001). The presence of DLN metastasis was asso-
ciated with a 4.4-fold higher frequency of lateral neck
LNM. Therefore, if DLN metastasis is detected after
surgery (even if lateral neck LNM was not detected on
preoperative imaging), we recommend vigilance for the
recurrence of lateral neck LNM during follow-up.dict contralateral central nodal disease
PPV NPV Positive likelihood ratio Negative likelihood ratio
45 90 4.6 0.68
45 93 7.0 0.68
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Since the presence of central neck LNM seems to be
associated with DLN metastasis, total thyroidectomy and
central neck lymph node dissection should be the first-
line treatment in patients with DLN metastasis. In con-
trast, when DLN metastasis is not observed in PTMC,
thyroid lobectomy on the affected side and ipsilateral
central neck lymph node dissection should be sufficient.
A retrospective investigation of the presence of central
neck LNM and metastasis pattern with respect to the
presence of DLN metastasis in patients who underwent
total thyroidectomy may yield more useful results for
planning the extent of surgery. In addition, if DLN
metastasis is detected after surgery (even if lateral neck
LNM was not detected on preoperative imaging), the
possibility of lateral neck LNM recurrence during
follow-up should be considered.
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